The End­points poll: A large ma­jor­i­ty of bio­phar­ma ex­ecs turn thumbs down on Bio­gen's con­tro­ver­sial pitch for ad­u­canum­ab

There’s a big vote loom­ing at the end of the week as out­side ex­perts at the FDA put Bio­gen’s Alzheimer’s drug ad­u­canum­ab on tri­al. But as far as the in­dus­try is con­cerned, most peo­ple in bio­phar­ma have al­ready made up their minds. And they’re turn­ing thumbs down on that drug in large num­bers.

More than a thou­sand peo­ple took our snap poll on the pan­el de­ci­sion com­ing on Fri­day, and 63% of them say the pan­el will vote to re­ject Bio­gen’s bid to gain an ap­proval on mixed da­ta from two late-stage stud­ies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.